Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein

被引:49
作者
Gonzalez, R
Vereecque, R
Wickham, TJ
Vanrumbeke, M
Kovesdi, I
Bauters, F
Fenaux, P
Quesnel, B
机构
[1] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[2] IRCL, INSERM, U124, Lille, France
[3] GenVec Inc, Rockville, MD USA
关键词
D O I
10.1038/sj.gt.3300836
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Applications of gene transfer in acute myeloid leukemia (AML) blast cells have still not been developed, mostly due to the lack of an efficient vector Adenoviruses have many advantages as vectors, but remain poorly efficient in cells lacking fiber receptors. A promising strategy is the retargeting of adenoviruses to other cellular receptors. We report the dramatic enhancement of gene transfer efficiency in AML blasts using AdZ.F(pK7), a modified adenovirus containing a heparin/heparan sulfate binding domain incorporated into the fiber protein of the adenovirus. We transduced 25 AML blast samples with efficiency reaching 100% of the cells in most samples. Optimal results were obtained at 8400 physical particles per cell, corresponding to a multiplicity of infection of 100 plaque forming units per cell. Control AdZ.F adenovirus efficiently transduced leukemic cell lines but gave poor results in AML samples. Both addition of soluble heparin and cell treatment with heparinase inhibited AdZ.F(pK7) gene transfer showing that heparan sulfates are the major receptors mediating AdZ.F(pK7) transduction of AML blasts. Although adenoviruses can infect nondividing cells, we observed that a combination of growth factors (GMCSF, IL-3, stem cell factor) was required for efficient transduction in order to maintain AML blast cell viability. This study demonstrates that retargeting the adenovirus fiber protein to heparan sulfates can overcome the low efficiency of adenovirus in AML blast cells and may provide a useful tool for gene therapy approaches in AML.
引用
收藏
页码:314 / 320
页数:7
相关论文
共 29 条
[11]   A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow [J].
Kim, MH ;
Wright, M ;
Deshane, J ;
Accavitti, MA ;
Tilden, A ;
Saleh, M ;
Vaughan, WP ;
Carabasi, MH ;
Rogers, MD ;
Hockett, RD ;
Grizzle, WE ;
Curiel, DT .
HUMAN GENE THERAPY, 1997, 8 (02) :157-170
[12]   Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism [J].
Krasnykh, VN ;
Mikheeva, GV ;
Douglas, JT ;
Curiel, DT .
JOURNAL OF VIROLOGY, 1996, 70 (10) :6839-6846
[13]   Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors [J].
Neering, SJ ;
Hardy, SF ;
Minamoto, D ;
Spratt, SK ;
Jordan, CT .
BLOOD, 1996, 88 (04) :1147-1155
[14]  
Seth P, 1996, CANCER RES, V56, P1346
[15]   HERPESVIRUS-INDUCED CELL-FUSION THAT IS DEPENDENT ON CELL-SURFACE HEPARAN-SULFATE OR SOLUBLE HEPARIN [J].
SHIEH, MT ;
SPEAR, PG .
JOURNAL OF VIROLOGY, 1994, 68 (02) :1224-1228
[16]   Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein [J].
Stevenson, SC ;
Rollence, M ;
MarshallNeff, J ;
McClelland, A .
JOURNAL OF VIROLOGY, 1997, 71 (06) :4782-4790
[17]   HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses [J].
Tomko, RP ;
Xu, RL ;
Philipson, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) :3352-3356
[18]   Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors [J].
Watanabe, T ;
Kuszynski, C ;
Ino, K ;
Heimann, DG ;
Shephard, HM ;
Yasui, Y ;
Maneval, DC ;
Talmadge, JE .
BLOOD, 1996, 87 (12) :5032-5039
[19]  
WATT SM, 1993, BLOOD, V82, P2649
[20]  
Wattel E, 1996, LEUKEMIA, V10, P171